This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Has the market gotten too complacent about these new highs? Jim Cramer told his Mad Money viewers Friday he thinks that might be the case, and next week's game plan will be a difficult road for the bulls.

Cramer said the markets will be ruled by two macro-economic events next week -- the European Central Bank's decision on interest rates on Thursday and the U.S. non-farm payroll numbers on Friday. Whatever stocks may gain earlier in the week can be easily be undone by these two events.

Then there's the Apple (AAPL) Worldwide Developers Conference that kicks off on Monday. Cramer said this stock, which he owns for his charitable trust, Action Alerts PLUS, has created 300,000 jobs in the burgeoning app economy and this conference should help buoy the markets.

Then, on Tuesday, Cramer said he'll be watching Dollar General (DG). While he generally likes the dollar group, Cramer said he'd bet on Target (TGT) with its 3% yield and its new CEO.

Wednesday brings earnings from Brown-Forman (BFB) and PVH Corp (PVH). Cramer said he'd be a buyer of Forman but would take profits and lock in gains with PVH because the stock has had a nice move higher.

On Thursday, J.M. Smucker (SJM), Ciena (CIEN), Joy Global (JOY) and Zoe's Kitchen (ZOES) will all be reporting. Cramer said he wants to hear Smucker's thoughts on the recent wave of consolidation in the food stocks, but he'd avoid Joy Global. He was also not a fan of Ciena, preferring Cisco Systems (CSCO), but does approve of owning Zoe's over the long term.

Executive Decision: Tom Pike

For his "Executive Decision" segment, Cramer sat down with Tom Pike, CEO of Quintiles Transnational (Q - Get Report), the company biotech firms turn to when they need to outsource their clinical trials. Quintiles just posted a 13-cents-a-share earnings beat on an 8.4% rise in revenue.

Pike said it's been an exciting year for Quintiles. He said there has been a ton of money flowing into biotech firms and that means more drugs that need testing and more business for Quintiles.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
CRM $73.36 0.00%
MSFT $48.66 0.00%
Q $67.30 0.00%
AAPL $128.95 0.00%
FB $78.99 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs